MedTrace Logo

Relapse Prevention to Reduce HIV Among Women Prisoners

NCT00763958 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2012-06-04

Study results available
· View outcomes & findings →

Summary

This study is a feasibility and acceptability study assessing whether providing buprenorphine for women under criminal justice supervision leaving a controlled environment and returning to the community would prevent opioid relapse and reduce HIV risk behaviors.

Conditions

  • Opioid Dependence
  • HIV

Interventions

DRUG

Placebo

Placebo to match buprenorphine administered for 3 months

DRUG

Buprenorphine

Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Alabama at Birmingham

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-09-30
Completion
2010-09-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00763958 on ClinicalTrials.gov